{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T13:52:44Z","timestamp":1753883564175,"version":"3.41.2"},"reference-count":20,"publisher":"The Endocrine Society","issue":"10","license":[{"start":{"date-parts":[[2024,9,18]],"date-time":"2024-09-18T00:00:00Z","timestamp":1726617600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,9,18]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Fibrous dysplasia (FD) is a chronic and progressive disorder of bone growth because of decreased osteoblast formation and osteoclast overactivity. Its main symptoms include pain, fracture, and irregular bone growth. Bisphosphonates are the mainstay of therapy for FD with a primary goal of pain relief. A 50-year-old woman presented to ophthalmology in March 2011 with intermittent proptosis, vertical diplopia, and orbital pain. A computed tomography scan of the head revealed a skull base lesion, which was confirmed to be fibrous dysplasia on bone biopsy. Because of significant headache, she was treated with IV pamidronate monthly starting November 2011, which led to pain reduction. Repeated attempts to decrease the frequency of pamidronate were unsuccessful because of breakthrough pain. Oral alendronate and risedronate did not control her symptoms. She remained on risedronate however because of its convenience. In August 2021, she was diagnosed with metastatic melanoma and started nivolumab. Her headache completely resolved for the first time in 10 years. Although nivolumab, a programmed death-1 blocker, has been used in the treatment of bone malignancy, it has not been previously studied in FD. By suppressing RANK ligand-related osteoclastogenesis, nivolumab decreases cancer-associated bone pain. Our case suggests a potential role for nivolumab in treating FD-associated pain.<\/jats:p>","DOI":"10.1210\/jcemcr\/luae165","type":"journal-article","created":{"date-parts":[[2024,9,18]],"date-time":"2024-09-18T09:11:32Z","timestamp":1726650692000},"source":"Crossref","is-referenced-by-count":0,"title":["A Potential Role for Nivolumab in the Treatment of Fibrous Dysplasia-Related Pain"],"prefix":"10.1210","volume":"2","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-7299-4342","authenticated-orcid":false,"given":"Mohammad","family":"Jay","sequence":"first","affiliation":[{"name":"Division of Endocrinology, Department of Medicine, University of Toronto , Toronto, ON M5S 1A1 ,","place":["Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cassandra","family":"Hawco","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Department of Medicine, Western University , London, ON N6A 5C1 ,","place":["Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristin K","family":"Clemens","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Department of Medicine, Western University , London, ON N6A 5C1 ,","place":["Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0150-8223","authenticated-orcid":false,"given":"Stan","family":"Van Uum","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Department of Medicine, Western University , London, ON N6A 5C1 ,","place":["Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"80","published-online":{"date-parts":[[2024,9,18]]},"reference":[{"issue":"5","key":"2024101805262946700_luae165-B1","doi-asserted-by":"crossref","first-page":"305","DOI":"10.5435\/00124635-200409000-00005","article-title":"Fibrous dysplasia","volume":"12","author":"Parekh","year":"2004","journal-title":"J Am Acad Orthop Surg."},{"key":"2024101805262946700_luae165-B2","doi-asserted-by":"crossref","first-page":"116819","DOI":"10.1016\/j.bone.2023.116819","article-title":"Denosumab use in bone fibrous dysplasia refractory to bisphosphonate: a retrospective multicentric study","volume":"174","author":"Trojani","year":"2023","journal-title":"Bone"},{"issue":"Suppl 1","key":"2024101805262946700_luae165-B3","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1186\/1750-1172-7-S1-S3","article-title":"Pathophysiology and medical treatment of pain in fibrous dysplasia of bone","volume":"7","author":"Chapurlat","year":"2012","journal-title":"Orphanet J Rare Dis"},{"key":"2024101805262946700_luae165-B4","doi-asserted-by":"crossref","first-page":"116157","DOI":"10.1016\/j.bone.2021.116157","article-title":"Periorbital inflammation associated with craniofacial fibrous dysplasia: report of three cases and review of the literature","volume":"153","author":"Theng","year":"2021","journal-title":"Bone"},{"issue":"7","key":"2024101805262946700_luae165-B5","doi-asserted-by":"crossref","first-page":"3603","DOI":"10.1172\/JCI133334","article-title":"PD-1 blockade inhibits osteoclast formation and murine bone cancer pain","volume":"130","author":"Wang","year":"2020","journal-title":"J Clin Invest"},{"key":"2024101805262946700_luae165-B6","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/B978-0-323-35955-9.00022-2","volume-title":"The Breast","author":"Joshi","year":"2018","edition":"Fifth Edition"},{"issue":"1","key":"2024101805262946700_luae165-B7","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1186\/s13023-019-1102-9","article-title":"Best practice management guidelines for fibrous dysplasia\/McCune-Albright syndrome: a consensus statement from the FD\/MAS international consortium","volume":"14","author":"Javaid","year":"2019","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"2024101805262946700_luae165-B8","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s00428-013-1437-x","article-title":"Locally aggressive fibrous dysplasia","volume":"463","author":"Kashima","year":"2013","journal-title":"Virchows Archiv"},{"issue":"4","key":"2024101805262946700_luae165-B9","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1054\/jocn.2002.1056","article-title":"Symptomatic cranial fibrous dysplasias: clinico-radiological analysis in a series of eight operative cases with follow-up results","volume":"9","author":"Sharma","year":"2002","journal-title":"J Clin Neurosci"},{"key":"2024101805262946700_luae165-B10","doi-asserted-by":"crossref","first-page":"877936","DOI":"10.3389\/fneur.2022.877936","article-title":"PD-1\/PD-L axis in neuroinflammation: new insights","volume":"13","author":"Manenti","year":"2022","journal-title":"Front Neurol"},{"issue":"4","key":"2024101805262946700_luae165-B11","doi-asserted-by":"crossref","first-page":"400","DOI":"10.3892\/etm.2021.9831","article-title":"Programmed cell death\u20131\/programmed cell death\u2013ligand 1 inhibitors exert antiapoptosis and antiinflammatory activity in lipopolysaccharide stimulated murine alveolar macrophages","volume":"21","author":"Jia","year":"2021","journal-title":"Exp Ther Med"},{"key":"2024101805262946700_luae165-B12","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.ejca.2021.04.034","article-title":"Immune checkpoint inhibitors in treatment of soft-tissue sarcoma: a systematic review and meta-analysis","volume":"152","author":"Saerens","year":"2021","journal-title":"Eur J Cancer"},{"issue":"6","key":"2024101805262946700_luae165-B13","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.3390\/cancers15061643","article-title":"Immunotherapy for soft tissue sarcomas: anti-PD1\/PDL1 and beyond","volume":"15","author":"Fazel","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"6","key":"2024101805262946700_luae165-B14","doi-asserted-by":"crossref","first-page":"331","DOI":"10.3109\/01676830.2015.1078380","article-title":"Bisphosphonate-induced orbital inflammation: a case series and review","volume":"34","author":"Pirbhai","year":"2015","journal-title":"Orbit"},{"issue":"10","key":"2024101805262946700_luae165-B15","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1359\/jbmr.1997.12.10.1746","article-title":"Long-term effects of intravenous pamidronate in fibrous dysplasia of bone","volume":"12","author":"Chapurlat","year":"1997","journal-title":"J Bone Miner Res"},{"issue":"4","key":"2024101805262946700_luae165-B16","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/S8756-3282(03)00221-7","article-title":"Effect of intravenous pamidronate on bone markers and local bone mineral density in fibrous dysplasia","volume":"33","author":"Parisi","year":"2003","journal-title":"Bone"},{"issue":"5","key":"2024101805262946700_luae165-B17","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/s00776-004-0809-0","article-title":"Oral alendronate treatment for polyostotic fibrous dysplasia: a case report","volume":"9","author":"Kitagawa","year":"2004","journal-title":"J Orthop Sci"},{"key":"2024101805262946700_luae165-B18","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1097\/00003086-200101000-00003","article-title":"Bisphosphonate therapy in fibrous dysplasia","volume":"382","author":"Lane","year":"2001","journal-title":"Clin Orthop Relat Res"},{"issue":"9","key":"2024101805262946700_luae165-B19","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41571-019-0218-0","article-title":"Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance","volume":"16","author":"Martins","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"2024101805262946700_luae165-B20","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1002\/jcb.25266","article-title":"Risks and benefits of bisphosphonate therapies","volume":"117","author":"Reyes","year":"2016","journal-title":"J Cell Biochem"}],"container-title":["JCEM Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcemcr\/article-pdf\/2\/10\/luae165\/59807896\/luae165.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcemcr\/article-pdf\/2\/10\/luae165\/59807896\/luae165.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,18]],"date-time":"2024-10-18T05:26:42Z","timestamp":1729229202000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcemcr\/article\/doi\/10.1210\/jcemcr\/luae165\/7759892"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,18]]},"references-count":20,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,9,18]]}},"URL":"https:\/\/doi.org\/10.1210\/jcemcr\/luae165","relation":{},"ISSN":["2755-1520"],"issn-type":[{"type":"electronic","value":"2755-1520"}],"subject":[],"published-other":{"date-parts":[[2024,10]]},"published":{"date-parts":[[2024,9,18]]},"article-number":"luae165"}}